The 10-second takeaway
For the quarter ended March 31 (Q1), NuVasive beat expectations on revenues and earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share dropped significantly.
Gross margins dropped, operating margins expanded, and net margins contracted.
NuVasive recorded revenue of $151.7 million. The 21 analysts polled by S&P Capital IQ expected a top line of $143.5 million on the same basis. GAAP reported sales were 22% higher than the prior-year quarter's $124.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.20. The 21 earnings estimates compiled by S&P Capital IQ predicted $0.18 per share. GAAP EPS of $0.02 for Q1 were 67% lower than the prior-year quarter's $0.06 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 75.7%, 540 basis points worse than the prior-year quarter. Operating margin was 4.8%, 110 basis points better than the prior-year quarter. Net margin was 0.4%, 150 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $153.5 million. On the bottom line, the average EPS estimate is $0.23.
Next year's average estimate for revenue is $616.5 million. The average EPS estimate is $0.93.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 158 members out of 178 rating the stock outperform, and 20 members rating it underperform. Among 45 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give NuVasive a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on NuVasive is outperform, with an average price target of $21.53.
The health-care investing landscape is littered with also-rans and a few major winners. Is NuVasive the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add NuVasive to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's What Pressured NuVasive, Inc. Stock Today
NuVasive went out of its way to present some mixed results.
5 Supernova Stocks That Have Flown Under the Radar: NuVasive
Among the 210 stocks David Gardner has on his active recommendation list, not all get the recognition they deserve in the markets.
Why Akamai Technologies, NuVasive, and MacroGenics Jumped Today
Even though the market slumped, these stocks gained ground. Find out why.